Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. CSL Limited
  6. News
  7. Summary
    CSL   AU000000CSL8


End-of-day quote. End-of-day quote Australian Stock Exchange - 09/17
309.36 AUD   +0.34%
09/12Australia's NSW state says coronavirus vaccination pace slows
09/12CSL : Positive COVID-19 Case at Broadmeadows
09/02CSL : Annual Report
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Seqirus Presents New Safety Data Demonstrating Safety of Cell-Based Seasonal Influenza Vaccine on Pregnancy Outcomes

07/30/2021 | 08:30am EDT

Seqirus a business of CSL Limited presented findings from a new observational safety study conducted in the U.S. that found no unexpected adverse pregnancy outcomes in pregnant people who were vaccinated with the company's cell-based quadrivalent seasonal influenza vaccine (QIVc) during pregnancy. These data were presented at the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Meeting on July 30, 2021. The prospective observational cohort study evaluated pregnancy outcomes and events of interest in the fetus or infant following vaccination with QIVc during any trimester. The findings from this study were reviewed by an independent Scientific Advisory Committee (SAC). Pregnant people are considered an at-risk population for influenza. Changes that occur in the immune system, heart and lungs during pregnancy can make those who are pregnant, and those who are up to two weeks postpartum, more prone to severe illness or complications from influenza. Influenza vaccination is the best way to prevent influenza and the Centers for Disease Control and Prevention (CDC) recommends seasonal influenza vaccine every year as the best way to prevent influenza for everyone six months of age and above who do not have contraindications. This recommendation extends to pregnant people as well. These clinical data are an addition to a growing body of evidence supporting the safety and utility of cell-based influenza vaccines like QIVc. The cell-based influenza vaccine, marketed in the U.S. as FLUCELVAX® QUADRIVALENT, is approved in the U.S. for use for the prevention of influenza disease in people two years and older and is currently under review with the U.S. Food and Drug Administration (FDA) for an expanded age indication for children as young as six months of age. QIVc utilizes a cell-based influenza vaccine manufacturing process, an alternative to traditional egg-based manufacturing.6 Cell-based influenza vaccines are designed to produce an exact match to those selected by the World Health Organization. Cell-based influenza vaccine technology may offer additional advantages over the standard influenza manufacturing process, including being more scalable and offering faster production in the event of an influenza pandemic. In the U.S., Seqirus operates a cell-based manufacturing facility in Holly Springs, North Carolina, purpose-built in partnership with the Biomedical Advanced Research and Development Authority (BARDA) to increase cell-based vaccine manufacturing capacity and combat pandemic influenza threats. Last year, Seqirus announced plans to build a new, world-class cell-based manufacturing facility in Australia, which will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere.

© S&P Capital IQ 2021
All news about CSL LIMITED
09/12Australia's NSW state says coronavirus vaccination pace slows
09/12CSL : Positive COVID-19 Case at Broadmeadows
09/02CSL : Annual Report
09/02CSL LIMITED : Ex-dividend day for final dividend
09/01Australian shares drop over 1% on BHP losses, COVID-19 worries
08/31Banks, miners drive Australian shares lower ahead of GDP data
08/30Australian shares rise on tech, miners boost; banks cap gains
08/19Seqirus Announces Investment in Next-Generation Influenza Vaccine Technology,..
08/18CSL : Uncertainty Prevails For CSL
08/17CSL's Plasma Collections on Track to Exceed Pre-Pandemic Levels, CEO Says
More news
Analyst Recommendations on CSL LIMITED
More recommendations
Financials (USD)
Sales 2022 10 600 M - -
Net income 2022 2 245 M - -
Net Debt 2022 3 708 M - -
P/E ratio 2022 45,7x
Yield 2022 0,96%
Capitalization 102 B 103 B -
EV / Sales 2022 10,0x
EV / Sales 2023 9,12x
Nbr of Employees 25 000
Free-Float 99,9%
Duration : Period :
CSL Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 224,75 $
Average target price 227,99 $
Spread / Average Target 1,44%
EPS Revisions
Managers and Directors
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Joy Carolyn Linton Chief Financial Officer
Brian Anthony McNamee Chairman
Andrew Cuthbertson Chief Scientific Officer & Executive Director
William Mezzanotte Chief Medical Officer, EVP & Head-R&D
Sector and Competitors